Nanobiotix Files March 2025 6-K Report
Ticker: NBTX · Form: 6-K · Filed: Mar 27, 2025 · CIK: 1760854
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, pharmaceuticals
TL;DR
NANO filed its March 6-K, standard update.
AI Summary
Nanobiotix S.A. filed a Form 6-K on March 27, 2025, to report its activities for the month of March 2025. The company, based in Paris, France, is a pharmaceutical preparations company.
Why It Matters
This filing provides an update on Nanobiotix's ongoing activities and regulatory compliance for the period. Investors can review this to stay informed about the company's operational status.
Risk Assessment
Risk Level: low — This is a routine filing providing general company information and does not contain significant new financial or strategic disclosures.
Key Players & Entities
- Nanobiotix S.A. (company) — Filer of the report
- Paris, France (location) — Company's principal executive office
- March 2025 (date) — Reporting period for the Form 6-K
- 20250327 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of March 2025.
What is Nanobiotix S.A.'s primary business sector?
Nanobiotix S.A. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where is Nanobiotix S.A. located?
The company's principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.
Does Nanobiotix S.A. file annual reports under Form 20-F?
Yes, Nanobiotix S.A. indicates it files annual reports under cover of Form 20-F.
What is the filing date of this report?
This report was filed on March 27, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 27, 2025 regarding Nanobiotix S.A. (NBTX).